New drug study aims to see how liver health affects medication

NCT ID NCT07401862

Recruiting now Knowledge-focused Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage study is testing a single dose of the drug eloralintide in 36 people with different levels of liver function—from healthy to severely impaired. Researchers want to see how the body absorbs and processes the drug and whether it causes side effects. The goal is to understand how liver damage might change the way the drug works, which could help guide future dosing recommendations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: eloralintide (LY3841136)
What this could lead to: If successful, this study will help determine safe dosing of eloralintide for people with liver problems, potentially guiding future treatment use.
What could go wrong: This is a very early Phase 1 study with only 36 participants. It is designed to measure drug levels and safety, not to treat any disease. Results may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hepatic Insufficiency liver disorder liver failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATIC INSUFFICIENCY

Contacts and locations

Locations

American Research Corporation
RECRUITING

San Antonio, Texas, 78215, United States
CRU Early Phase Unit
RECRUITING

Kistarcsa, H-2143, Hungary
Orlando Clinical Research Center
RECRUITING

Orlando, Florida, 32809, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.